Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016
Published Jun 15, 2016
96 pages — Published Jun 15, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016, provides in depth analysis on Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted pipeline therapeutics.

The report provides comprehensive information on the Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)
- The report reviews Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effectiv

  
Source:
Document ID
GMDHC0073TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Overview91
Therapeutics Development104
  Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Stage of Development101
  Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Therapy Area111
  Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Indication122
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Pipeline Products Glance143
  Late Stage Products141
  Early Stage Products151
  Unknown Stage Products161
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Companies174
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Universities/Institutes212
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Therapeutics Assessment236
  Assessment by Monotherapy/Combination Products231
  Assessment by Mechanism of Action241
  Assessment by Route of Administration252
  Assessment by Molecule Type272
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Companies Involved in Therapeutics Development2911
  Akari Therapeutics, Plc291
  Alexion Pharmaceuticals, Inc.301
  Alnylam Pharmaceuticals, Inc.311
  Amgen Inc.321
  Epirus Biopharmaceuticals, Inc.331
  InflaRx GmbH341
  Novartis AG351
  Noxxon Pharma AG361
  Ophthotech Corp.371
  Ra Pharmaceuticals, Inc.381
  Swedish Orphan Biovitrum AB391
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Drug Profiles4041
  AcPepA Drug Profile401
  ALN-CC5 Drug Profile414
  ALXN-1007 Drug Profile451
  ALXN-1210 Drug Profile461
  ALXN-5500 Drug Profile471
  avacincaptad pegol sodium Drug Profile482
  Bikaciomab Drug Profile501
  BikajuMab Drug Profile511
  Coversin Drug Profile523
  eculizumab Drug Profile5510
  eculizumab biosimilar Drug Profile651
  eculizumab biosimilar Drug Profile661
  IFX-1 Drug Profile672
  IFX-2 Drug Profile691
  Monoclonal Antibody for Ischemia Reperfusion Injury Drug Profile701
  NM-9405 Drug Profile711
  NOXD-21 Drug Profile721
  Protein to Inhibit Complement C5 for Immunology Drug Profile731
  RA-101295 Drug Profile741
  RA-101348 Drug Profile751
  RA-101495 Drug Profile761
  SOBI-005 Drug Profile771
  Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation Drug Profile781
  tesidolumab Drug Profile792
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Dormant Projects812
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Discontinued Products831
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Featured News &Press Releases8411
  Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery841
  Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG)842
  Jun 03, 2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data861
  Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)861
  May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barr Syndrome871
  May 19, 2016: Researchers to Present Additional Data, Including Late-Breaking Results on ALXN1007 in Patients with GI-GVHD at EHA Annual Congress871
  May 19, 2016: Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated881
  May 19, 2016: Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress891
  May 19, 2016: Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association891
  May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barr Syndrome901
  May 09, 2016: EPIRUS Announces Reprioritization of Pipeline, to focus on biosimilar product BOW080911
  Mar 31, 2016: Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin911
  Feb 16, 2016: A Statement from the Executive Officer of the Ontario Public Drug Programs on behalf of the pCPA921
  Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines &Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial931
  Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody932
Appendix952
  Methodology951
  Coverage951
  Secondary Research951
  Primary Research951
  Expert Panel Validation951
  Contact Us951
  Disclaimer961

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Complement-C5-C3-And-PZP-Like-Alpha-2-Macroglobulin-Domain-Containing-Protein-4-Pipeline-Review-H1-2016-2088-15965>
  
APA:
Global Markets Direct - Market Research. (2016). Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Complement-C5-C3-And-PZP-Like-Alpha-2-Macroglobulin-Domain-Containing-Protein-4-Pipeline-Review-H1-2016-2088-15965>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.